Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19.

ABSTRACT:

Background

clozapine (CLZ) use is precarious due to its neurological, cardiovascular, and hematological side effects; however, it is the gold standard in therapy-resistant schizophrenia (TRS) in adults and is underused.

Objective

to examine the most recent CLZ data on (a) side effects concerning (b) recent pharmacological mechanisms, (c) therapy benefits, and (d) the particularities of the COVID-19 pandemic.

Data sources

a search was performed in two databases (PubMed and Web of Science) using the specific keywords "clozapine" and "schizophrenia", "side effects", "agranulocytosis", "TRS", or "bipolar affective disorder (BAF)" for the last ten years.

Study eligibility criteria

clinical trials on adults with acute symptoms of schizophrenia or related disorders.

SUBMITTER: Dragoi AM 

PROVIDER: S-EPMC7697202 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature